Intravitreal injections of anti-vascular endothelial growth factor (VEGF) are now established as the best treatment modality for macular neovascularization (MNV) secondary to age-related macular degeneration (AMD) [1-4]. The gene discussed is VEGFA; the disease is age-related macular degeneration.